Celsion (NASDAQ:CLSN) Cut to “Strong Sell” at ValuEngine

ValuEngine lowered shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday, November 15th.

Other analysts have also recently issued reports about the stock. Maxim Group reiterated a hold rating on shares of Celsion in a research note on Tuesday, August 15th. Zacks Investment Research cut shares of Celsion from a buy rating to a hold rating in a research note on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $11.90.

Shares of Celsion (CLSN) opened at $2.60 on Wednesday. Celsion has a 52 week low of $1.24 and a 52 week high of $9.94.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new position in Celsion Corporation (NASDAQ:CLSN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.15% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://weekherald.com/2017/12/04/valuengine-lowers-celsion-corporation-clsn-to-strong-sell.html.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply